276 related articles for article (PubMed ID: 25846049)
1. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma.
Yoshikawa K; Noguchi K; Nakano Y; Yamamura M; Takaoka K; Hashimoto-Tamaoki T; Kishimoto H
Int J Oncol; 2015; 46(6):2364-70. PubMed ID: 25846049
[TBL] [Abstract][Full Text] [Related]
2. Copper efflux transporter (ATP7B) contributes to the acquisition of cisplatin-resistance in human oral squamous cell lines.
Yoshizawa K; Nozaki S; Kitahara H; Ohara T; Kato K; Kawashiri S; Yamamoto E
Oncol Rep; 2007 Oct; 18(4):987-91. PubMed ID: 17786364
[TBL] [Abstract][Full Text] [Related]
3. Ailanthone inhibits cell growth and migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2, YAP, and c-Myc expression.
Daga M; Pizzimenti S; Dianzani C; Cucci MA; Cavalli R; Grattarola M; Ferrara B; Scariot V; Trotta F; Barrera G
Phytomedicine; 2019 Mar; 56():156-164. PubMed ID: 30668336
[TBL] [Abstract][Full Text] [Related]
4. LncRNA UCA1 promotes proliferation and cisplatin resistance of oral squamous cell carcinoma by sunppressing miR-184 expression.
Fang Z; Zhao J; Xie W; Sun Q; Wang H; Qiao B
Cancer Med; 2017 Dec; 6(12):2897-2908. PubMed ID: 29125238
[TBL] [Abstract][Full Text] [Related]
5. A YAP/TAZ-Regulated Molecular Signature Is Associated with Oral Squamous Cell Carcinoma.
Hiemer SE; Zhang L; Kartha VK; Packer TS; Almershed M; Noonan V; Kukuruzinska M; Bais MV; Monti S; Varelas X
Mol Cancer Res; 2015 Jun; 13(6):957-68. PubMed ID: 25794680
[TBL] [Abstract][Full Text] [Related]
6. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
[TBL] [Abstract][Full Text] [Related]
7. Reversal of cisplatin resistance in oral squamous cell carcinoma by piperlongumine loaded smart nanoparticles through inhibition of Hippo-YAP signaling pathway.
Sa P; Singh P; Panda S; Swain RK; Dash R; Sahoo SK
Transl Res; 2024 Jun; 268():63-78. PubMed ID: 38499286
[TBL] [Abstract][Full Text] [Related]
8. YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation.
Hasegawa K; Fujii S; Matsumoto S; Tajiri Y; Kikuchi A; Kiyoshima T
J Pathol; 2021 Jan; 253(1):80-93. PubMed ID: 32985688
[TBL] [Abstract][Full Text] [Related]
9. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
10. Yes-associated protein promotes cell proliferation by activating Fos Related Activator-1 in oral squamous cell carcinoma.
Zhang L; Ye DX; Pan HY; Wei KJ; Wang LZ; Wang XD; Shen GF; Zhang ZY
Oral Oncol; 2011 Aug; 47(8):693-7. PubMed ID: 21708480
[TBL] [Abstract][Full Text] [Related]
11. MiR-132 inhibits migration and invasion and increases chemosensitivity of cisplatin-resistant oral squamous cell carcinoma cells via targeting TGF-β1.
Chen L; Zhu Q; Lu L; Liu Y
Bioengineered; 2020 Dec; 11(1):91-102. PubMed ID: 31906769
[TBL] [Abstract][Full Text] [Related]
12. Quercetin acts as a novel anti-cancer drug to suppress cancer aggressiveness and cisplatin-resistance in nasopharyngeal carcinoma (NPC) through regulating the yes-associated protein/Hippo signaling pathway.
Li T; Li Y
Immunobiology; 2023 Mar; 228(2):152324. PubMed ID: 36608594
[TBL] [Abstract][Full Text] [Related]
13. TEAD4-YAP interaction regulates tumoral growth by controlling cell-cycle arrest at the G1 phase.
Takeuchi S; Kasamatsu A; Yamatoji M; Nakashima D; Endo-Sakamoto Y; Koide N; Takahara T; Shimizu T; Iyoda M; Ogawara K; Shiiba M; Tanzawa H; Uzawa K
Biochem Biophys Res Commun; 2017 Apr; 486(2):385-390. PubMed ID: 28315328
[TBL] [Abstract][Full Text] [Related]
14. YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma.
Yang C; Tan J; Zhu J; Wang S; Wei G
Oncotarget; 2017 Jun; 8(23):37154-37163. PubMed ID: 28415761
[TBL] [Abstract][Full Text] [Related]
15. YAP promotes erlotinib resistance in human non-small cell lung cancer cells.
Hsu PC; You B; Yang YL; Zhang WQ; Wang YC; Xu Z; Dai Y; Liu S; Yang CT; Li H; Hu B; Jablons DM; You L
Oncotarget; 2016 Aug; 7(32):51922-51933. PubMed ID: 27409162
[TBL] [Abstract][Full Text] [Related]
16. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
17. The Characteristic of S100A7 Induction by the Hippo-YAP Pathway in Cervical and Glossopharyngeal Squamous Cell Carcinoma.
Kong F; Li Y; Hu E; Wang R; Wang J; Liu J; Zhang J; He D; Xiao X
PLoS One; 2016; 11(12):e0167080. PubMed ID: 27907036
[TBL] [Abstract][Full Text] [Related]
18. Hippo/YAP signaling pathway is involved in osteosarcoma chemoresistance.
Wang DY; Wu YN; Huang JQ; Wang W; Xu M; Jia JP; Han G; Mao BB; Bi WZ
Chin J Cancer; 2016 May; 35():47. PubMed ID: 27206784
[TBL] [Abstract][Full Text] [Related]
19. The Hippo component YAP localizes in the nucleus of human papilloma virus positive oropharyngeal squamous cell carcinoma.
Alzahrani F; Clattenburg L; Muruganandan S; Bullock M; MacIsaac K; Wigerius M; Williams BA; Graham ME; Rigby MH; Trites JR; Taylor SM; Sinal CJ; Fawcett JP; Hart RD
J Otolaryngol Head Neck Surg; 2017 Feb; 46(1):15. PubMed ID: 28222762
[TBL] [Abstract][Full Text] [Related]
20. miR‑375/Yes‑associated protein axis regulates IL‑6 and TGF‑β expression, which is involved in the cisplatin‑induced resistance of liver cancer cells.
Yu K; Li H; Jiang Z; Hsu HJ; Hsu HC; Zhang Y; Wang K
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34132362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
